Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by HM Payson & Co.

HM Payson & Co. decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.5% during the first quarter, Holdings Channel.com reports. The firm owned 6,825 shares of the medical equipment provider’s stock after selling 249 shares during the period. HM Payson & Co.’s holdings in Zimmer Biomet were worth $901,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. OLD Point Trust & Financial Services N A purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $26,000. Crewe Advisors LLC purchased a new position in Zimmer Biomet in the 1st quarter valued at $31,000. Ables Iannone Moore & Associates Inc. purchased a new position in Zimmer Biomet in the 4th quarter valued at $30,000. J.Safra Asset Management Corp lifted its holdings in Zimmer Biomet by 712.1% in the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 235 shares in the last quarter. Finally, Naples Money Management LLC purchased a new position in Zimmer Biomet in the 4th quarter valued at $35,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of research reports. Citigroup decreased their price objective on Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Evercore ISI reduced their price target on Zimmer Biomet from $130.00 to $115.00 and set an “in-line” rating on the stock in a report on Tuesday, July 2nd. The Goldman Sachs Group assumed coverage on Zimmer Biomet in a report on Thursday, May 30th. They set a “neutral” rating and a $129.00 price target on the stock. Oppenheimer lifted their price target on Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Finally, Argus upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Tuesday, May 21st. One analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $129.81.

Zimmer Biomet Trading Down 0.7 %

NYSE ZBH traded down $0.76 during trading on Friday, hitting $110.36. The stock had a trading volume of 1,190,049 shares, compared to its average volume of 1,378,932. The company has a market capitalization of $22.70 billion, a PE ratio of 23.89, a PEG ratio of 1.99 and a beta of 1.01. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The firm has a 50 day moving average price of $109.75 and a 200 day moving average price of $119.11. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the previous year, the company posted $1.89 earnings per share. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend was Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio is presently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.